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compared with BEV  IFN and sunitinib. METHODS: A linear decision analytic
model was developed to assess the management costs of all-grade and grade 3/4 AEs
for BEV  LD IFN from the perspective of health care purchasers in Germany, France
and UK. Data sources included published cost literature and clinical trials, ofﬁ cial
price/tariff lists and country-speciﬁ c cost databases. RESULTS: The total side-effect 
management costs for BEV  LD IFN were €908, €1,381 and €703 in Germany, France
and UK, respectively. The use of BEV  LD IFN provides reduced management costs 
per patient of €616, €576 and €606, respectively, compared with BEV  IFN, and
€1,286, €3,746 and €1,647, respectively, compared with sunitinib. The main drivers 
for sunitinib costs were thrombocytopenia, neutropenia and lymphopenia compared 
with fatigue/asthenia, proteinuria and anaemia for BEV  LD IFN. CONCLUSIONS:
Costs of managing the side effects of sunitinib treatment are greater than those for 
BEV  IFN in Germany, France and UK [Mickisch, ASCO 2008]. The present analysis 
shows that combining BEV with LD IFN is associated with the lowest side effect 
management costs. The tolerability proﬁ les and associated management costs of agents
used in mRCC may therefore inﬂ uence selection of therapy.
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OBJECTIVES: The combination of BEV  interferon-alpha2a (IFN) prolongs progres-
sion-free survival compared with IFN  placebo [Escudier, Lancet 2007], providing 
comparable efﬁ cacy to sunitinib in patients with mRCC. Notably, the type and fre-
quency of side effects differ between the two regimens. When selecting treatment 
options, the management of side effects and associated costs are important factors to 
consider for physicians and health care payers. A previous report showed that grade 
3/4 adverse events (AEs) account for the majority of side-effect management costs 
[Mickisch, ASCO 2008]. We report here the results of an updated analysis of grade 
3/4 AE management costs for BEV  IFN and sunitinib. METHODS: A linear decision
analytic model was developed to compare the management costs of grade 3/4 AEs of 
BEV  IFN and sunitinib from the perspective of health care purchasers or hospital-
based care in Germany, France, the UK and Italy. Data sources included published 
cost literature and clinical trials, ofﬁ cial price/tariff lists and country-speciﬁ c cost 
databases. RESULTS: The grade 3/4 AE management costs for sunitinib were higher
than those for BEV  IFN in Germany (€1785 vs €1367), France (€2590 vs. €1618), 
UK (€1475 vs. €804) and Italy (€891 vs. €402). The main cost drivers were country
dependent, but in general were lymphopenia, leucopenia, neutropenia, thrombocyto-
penia and fatigue/asthenia for sunitinib; the main cost drivers for BEV  IFN were
proteinuria, fatigue/asthenia, bleeding, anaemia and gastrointestinal perforation. The
difference in management costs between the two regimens was mainly due to the 
higher incidence of haematological side effects with sunitinib compared with BEV 
IFN and their associated high management costs. CONCLUSIONS: The costs of 
managing AEs of sunitinib are greater than those for BEV  IFN in Germany, France,
UK and Italy. AE proﬁ les are therefore an important consideration when selecting
treatments for mRCC.
PCN18
ECONOMIC IMPACT OF SEVERE INFUSION REACTIONS IN PATIENTS
WITH COLORECTAL CANCER TREATED WITH CETUXIMAB
Foley KA1, Wang PF2, Barber B2, Long SR3, Bagalman JE4, Zhao Z2
1Thomas Jefferson University, Philadelphia, PA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA, 
3Thomson Reuters, Hampden, ME, USA, 4Thomson Reuters, WASHINGTON, DC, USA
OBJECTIVES: To assess the incidence rate and risk factors of severe infusion reactions 
(IRs), and to quantify the costs associated with their management in patients with 
colorectal cancer (CRC) treated with cetuximab. METHODS: Using administrative 
claims of a US national commercially insured population, the study evaluates patients
with CRC receiving cetuximab treatment from 2004 to 2006. An algorithm was 
developed to identify IRs using a combination of three indicators: outpatient diagnoses 
of signs/symptoms of IRs, outpatient treatment for IRs, and ER visits or hospitaliza-
tions for IRs. IRs were categorized as severe based on the occurrence of an ER visit/
hospitalization with an IR admitting diagnosis; or presence of both outpatient diag-
nosis of IR signs/symptoms and outpatient IR treatment. Total costs associated with
each cetuximab administration were calculated. A logistic regression was run to iden-
tify risk factors for IRs. A Generalized Linear Model regression controlling for demo-
graphic and clinical characteristics was conducted to quantify additional economic
impact of severe IRs. RESULTS: A total of 1,122 patients were identiﬁ ed with 12,367 
cetuximab administrations. The incidence of severe IRs was 8.4%. Approximately
38% of patients experiencing severe IRs required an ER visit or hospitalization. Mean 
adjusted costs were $6,339 for administrations resulting in a severe IR that required 
outpatient treatment only; $13,174 for administrations resulting in a severe IR that
required an ER visit or hospitalization; and $4,450 for administrations without an 
IR. Younger age was associated with a statistically higher likelihood of IRs. Living in
states with high pollen counts also had a trend of increased likelihood of severe IRs,
although it was not statistically signiﬁ cant. CONCLUSIONS: The rate of severe IRs
with cetuximab in clinical practice was found to be higher than that reported in the
product labeling and clinical trials. Total costs associated with managing severe IRs 
to payers were substantial.
CANCER – Cost Studies
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OBJECTIVES: Myeloid growth factors are used to treat and prevent chemotherapy-
induced neutropenia (CIN). Filgrastim and its long-acting version pegﬁ lgrastim are
granulocyte colony-stimulating factors (G-CSF), whereas sargramostim is a dual 
granulocyte-macrophage colony-stimulating factor (GM-CSF). This study analyzed 
the budget impact of substituting GM-CSF for G-CSF in the management of CIN from 
the perspective of a US health plan. METHODS: A spreadsheet model was developed
to compute annual and per-member-per-month (PMPM) costs associated with CSFs.
Inputs included cancer prevalence, the proportion of patients receiving chemotherapy 
and G/GM-CSFs, incidence and treatment cost of relevant adverse events (e.g., bone 
pain), and G/GM-CSF drug acquisition and administration costs. Incidence and cost 
of infection- and febrile neutropenia-related hospitalizations, based on recent analysis 
of medical insurance claims data, were also used. Cost savings (2006 USD) were
assessed for utilization share switches from G-CSF to GM-CSF. RESULTS: For a health 
plan with 1 million members, an estimated 976 patients received G/GM-CSF annually.
Modifying baseline utilization shares for pegﬁ lgrastim, ﬁ lgrastim, and sargramostim
of 70/30/0%, respectively, to alternative shares of 50/25/25% yielded almost $2 
million in annual cost savings, or $0.161 PMPM. Most of the cost savings were 
attributed to CSF acquisition and administration costs (81.8%), with lesser savings 
also observed for hospitalizations (14.6%) and adverse events (3.6%). Savings for
patients switching from pegﬁ lgrastim were greater than for patients switching from
ﬁ lgrastim. Results were sensitive to assumptions for drug cost and frequency of 
administration, but cost savings were observed for most scenarios. CONCLUSIONS:
This study suggests that health plans can realize substantial cost savings by substituting 
sargramostim for ﬁ lgrastim and pegﬁ lgrastim in CIN patients. With 25% of sar-
gramostim substitution, cost savings could reach more than 16 cents PMPM for a
typical US health plan.
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OBJECTIVES: Pemetrexed plus cisplatin (Cis/Pem) was recently approved in the US
as initial treatment for advanced nonsquamous NSCLC. We developed a budget 
impact model to estimate the effect on a US health plan budget of adopting Cis/Pem
for this new indication. METHODS: A deterministic Excel-based budget impact model
was developed from the perspective of a one million member US health plan over a 
one-year time horizon. A survey of nine US thoracic oncologists was used to quantify
the impact of introducing Cis/Pem as ﬁ rst-line therapy on the frequency of chemo-
therapy use and the choice of ﬁ rst- and second-line regimens. Results were calculated 
from SEER incidence rates and the anticipated changes in ﬁ rst- and second-line 
regimen utilization rates. The costs associated with each regimen were based on 
Medicare reimbursement rates and a claims database analysis. Model outputs included
health plan total cost, cost per patient per year, and per member per month (PMPM) 
costs. RESULTS: Following the adoption of Cis/Pem, total cost per patient per year 
for advanced NSCLC is estimated to decrease by $702 from $67,539 to $66,837.
Anticipating that the number of NSCLC patients receiving treatment over the course
of one year would increase slightly, a net additional cost to the health plan of $35,512 
is estimated. Overall a neutral PMPM cost ($0.00) is expected. Most sensitivity analy-
ses produce PMPM costs between $0.02 and $0.02. CONCLUSIONS: Introduction 
of Cis/Pem as ﬁ rst-line therapy is anticipated to reduce the use of less expensive doublet 
regimens including gemcitabine and paclitaxel; however, it is also anticipated to reduce 
the use of more expensive triplet regimens containing bevacizumab. When Cis/Pem is 
used as ﬁ rst-line therapy, alternative, and often less expensive, regimens are recom-
mended for use as second-line therapy. Overall, the adoption of Cis/Pem as ﬁ rst-line 
therapy for advanced nonsquamous NSCLC is anticipated to be budget neutral.
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OBJECTIVES: to assess the ﬁ nancial consequences of the introduction of erlotinib as
second/third line treatment of patients with IIIB/IV NSCLC in Poland. METHODS:
Two scenarios were compared: “baseline scenario” where 96% patients received 
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docetaxel 75 mg/m2 every 21 days and 4% received pemetrexed 500 mg/m2 every 21 
days versus “new scenario” where 100% patients were treated with erlotinib 150 mg/
d. To assess the impact of disease progression, survival, safety proﬁ le and estimate 
costs after starting a therapy, a Markov health-state model was developed. Budget 
impact was derived by simulating a patient cohort progress through the model and
allowing for new eligible patients to enter the model each year. For each scenario 
the model computes annual costs for 3-years time horizon. Only direct medical costs 
were included and estimated from the health care payer perspective. All costs were 
assessed in PLN (1 EUR  4.03 PLN, 2008), without discounting. Extreme scenario
sensitivity analyses were performed. RESULTS: Assuming that the number of patients
eligible for erlotinib therapy would be 200 annually, substitution of “baseline sce-
nario” with erlotinib is expected to reduce expenditure by 251,344 PLN, 517,116 
PLN and 533,012 PLN in the 1st, 2nd and 3rd year, respectively (1,301,472 PLN over 
3 years). Savings are mostly associated with oral administration of erlotinib. Sensitivity
analysis shows that depending on assumptions regarding the costs of intravenous
administration of docetaxel and pemetrexed or market share of docetaxel and peme-
trexed, substitution with erlotinib could result in savings of up to 1,358,635 PLN over 
3 years or to cost increases of up to 508,732 PLN over 3 years. CONCLUSIONS:
Given the results of this budget impact simulation in the treatment of patients with 
second/third line metastatic NSCLC, erlotinib offers potential cost-savings to docetaxel 
and pemetrexed.
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PHARMACOECONOMIC APPLICATIONS IN FORMULARY
MANAGEMENT: BUDGET IMPACT ANALYSIS OF CLORFARABINE 
AT A MAJOR CANCER CENTER
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OBJECTIVES: Develop a budget impact analysis to present to the Pharmacy and
Therapeutics (P&T) Committee for approval of clorfarabine (FDA-approved for ALL 
in December 2004) to the institution’s Formulary for acute lymphoblastic leukemia 
(ALL). A post-approval study was performed to assess the accuracy and validity of 
our model. METHODS: A pre-approval annual budget impact model for clorfarabine 
was developed for an institutional population of 24 ALL patients, and presented to 
P&T in May 2005. Assumptions regarding clorfarabine’s number of doses per
cycle and median number of cycles per patient were estimated from published clinical
trials and clinicians estimated use. In August 2008, a post-approval economic analysis 
was conducted to assess the actual annual budget impact of clorfarabine. We reviewed
all use (excluding investigational) of clorfarabine from June 2006 through May 
2007. We also reviewed charge and reimbursement data for clorfarabine for the
same time period. All costs were adjusted to 2008 dollars. RESULTS: During the
study period for the post-approval analysis, we treated 23 patients with clorfarabine;
of these, only 5 (22%) were for ALL, 13 (56%) for acute myelogenous leukemia and 
5 (22%) for other indications. For the ALL population, we had a positive reimburse-
ment margin, and reimbursement to charge ratio was 77%. For all indications, the 
overall reimbursement to charge ratio for clorfarabine was 53%. Actual budget impact 
was $1,105,598; less than the $2,430,000 predicted from the pre-approval model. 
CONCLUSIONS: The result of the post-approval budget impact analysis of clorfara-
bine was lower than that estimated by the pre-approval model. Our pre-approval 
model included only ALL patients and overestimated the number of patients actually 
treated. Major factors driving the difference between the pre- and post-approval 
studies were actual drug cost per dose, actual number of doses per patient, and 
off-label usage. Future studies will include estimation of off-label usage in the pre-
approval model.
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OBJECTIVES: To estimate the impact of docetaxel reimbursement in the induction
therapy of locally advanced head and neck squamous cell carcinoma (HNSCC) on the 
budget of the Public Payer in Poland. Strategy containing docetaxel (TPF – docetaxel/
cisplatin/ﬂ uorouracil) was compared with the standard strategy of induction treatment 
(PF – cisplatin/ﬂ uorouracil), reimbursed in Poland. METHODS: The budget impact 
analysis was performed in 5 years time horizon (years 2008–2012). Analysis was 
performed from the public payer’s perspective (National Health Fund) in Poland. Two
scenarios were compared: present and future. In the “present scenario” it was assumed
that all patients from target population will be treated with standard chemotherapy – 
PF. In the “future scenario” induction treatment of locally advanced HNSCC with 
scheme with docetaxel (TPF) was considered. Sensitivity analysis was performed to
test the impact of changes in the key assumptions of the analysis. Additionally, the
analyses of the best and the worst case scenarios were performed. RESULTS: Esti-
mated number of target population qualiﬁ ed for induction therapy of locally advanced 
head and neck cancer will amount from 483 patients in 2008 to 488 patients in 2012. 
Assuming the reimbursement of docetaxel in treatment of locally advanced HNSCC,
annual expenses from budget of National Health Fund would raise by PLN3.54 
million in 2008, PLN3.96 million in 2009, PLN3.97 million in 2010, PLN3.98 million 
in 2011 and PLN3.99 million in year 2012. Incremental LYG will amount from 296
to 299 years in 2008 to 2012 respectively. CONCLUSIONS: Docetaxel reimbursement 
in the treatment of locally advanced HNSCC will not considerably inﬂ uence the
expenses of the Public Payer in Poland. Treatment with docetaxel improves survival 
compared with standard care.
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OBJECTIVES: Rasburicase is a recombinant urate-oxidase enzyme that reduces high 
levels of plasma uric acid (UA) resulting from tumor lysis syndrome (TLS). Rasburicase 
reduces UA levels within four hours of administration, minimizing risk of serious 
complications from TLS. Treatment pattern analyses indicate rasburicase is often used 
in combination with allopurinol; however, no studies have evaluated the clinical and
economic consequences of this pattern of care. This study compared hospitalization 
costs, length of stay, and duration of critical care in patients receiving rasburicase with
or without allopurinol. METHODS: Patients within the Premier hospital database
administered rasburicase or combination therapy in the ﬁ rst two days of hospital 
admission were eligible for study inclusion. Patients were excluded if they were aged 
 18 years or received hemodialysis on admission. Patients were propensity score 
matched to rasburicase based on gender, race, hospital type, provider type, payer type, 
admission source, use of electrolyte modiﬁ cation therapy, critical care admission, and 
comorbid diagnoses. Differences in health care costs, length of stay, and duration of 
subsequent critical care were assessed using gamma distributed generalized linear 
models with a log link function. Projection weights were used to produce national 
projected patient counts. RESULTS: There were 280 rasburicase and 310 combination
patients matched in the analysis. The mean age was 65.2 years, with 31% being 
female. No statistical differences existed in matched covariates across the cohorts. 
Rasburicase patients incurred an average total cost of $39,245 per hospitalization 
compared to $52,402 for combination patients (p  0.0534). Rasburicase patients also 
had a lower length of stay (10.2 days) compared to combination therapy (16.1 days, 
p  0.0047). Duration of critical care was similar in both cohorts (rasburicase  2.9 
days vs 3.1 days, p  0.792). CONCLUSIONS: Combination therapy of rasburicase 
and allopurinol resulted in higher total hospitalization costs and a longer length of 
stay compared to rasburicase monotherapy.
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OBJECTIVES: To evaluate recent utilization patterns and costs for epoetin alfa (EPO) 
and darbepoetin alfa (DARB) across tumor types in managed care cancer patients
receiving chemotherapy. METHODS: Medical claims from the Ingenix Impact 
National Managed Care Database between January 2006-June 2008 were analyzed.
Patients included were q18 years, had q1 claim for cancer within 90 days prior to 
treatment initiation, were newly initiated on EPO or DARB with q2 doses of 
either drug, and received chemotherapy during treatment. Mean cumulative ESA 
dose was used to calculate drug cost (based on 10/08 wholesale acquisition cost) and 
dose ratio (Units EPO : mcg DARB). Stratiﬁ ed analyses for breast, lung, and gastroin-
testinal cancer patients were also conducted. RESULTS: A total 9,790 patients (EPO: 
3812; DARB: 5978) formed the study population. Breast, lung and gastrointestinal 
cohorts comprised 3277, 2226, and 1755 patients respectively.The EPO group was
slightly older (58.5 vs. 56.4 years, p  0.001), had a lower proportion of women (64% 
vs. 68%, p  0.001), and had similar treatment duration (EPO: 68 days; DARB: 67 
days; p  0.191), compared to DARB patients. The mean cumulative dose (SD) was 
308,344 (257,539) Units for EPO and 1,222 (890) mcg for DARB, resulting in a dose 
ratio of 252:1. Based on the observed utilization of ESAs, drug cost was 28% lower
for EPO than for DARB (EPO $4246; DARB $5889; p  0.001). Stratiﬁ ed analyses 
by tumor type resulted in similar lower drug costs for EPO-Breast: 29% (EPO $4206;
DARB $5883), Lung: 26% (EPO $4606; DARB $6232), Gastrointestinal: 31% (EPO
$3,988; DARB $5812), respectively, (p  0.001 for all comparisons). CONCLU-
SIONS: This observational study of 9790 cancer patients receiving chemotherapy
reported a dose ratio of 252:1 which resulted in a 28% lower drug cost in the EPO
group compared to the DARB group. Stratiﬁ ed analyses by major tumor types yielded 
similar ﬁ ndings.
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OBJECTIVES: To examine recent real-world dosing patterns and associated drug costs
of epoetin alfa (EPO) and darbepoetin alfa (DARB), two erythropoiesis-stimulating 
agents (ESAs), in hospitalized patients with cancer who were receiving chemotherapy.
METHODS: An analysis of recent electronic inpatient records (2006–2007) from the 
Premier Perspective Comparative Hospital Database was conducted. Patients were q18 
